Additionally, inhibition of the 5-phosphatase activity of Synj1 has also been found to hold promise toward drug development for TBC1D24-associated epilepsy and DOORS syndrome (Fischer et al., 2016; Lüthy et al., 2019). Here, SYNJ1 is linked to DOORS syndrome.